Description

Patients with esophageal cancer admitted to Hubei Provincial People's Hospital from May 2023 to December 2024 were collected (the estimated number of patients included is 60). Collect research objects: 1. Baseline information: gender, age, tumor location, T stage, N stage, and BMI, etc. The tumor staging and grading are determined according to the eighth edition of American Joint Committee on Cancer esophageal cancer staging; 2. Laboratory data; Blood routine, liver and kidney function, electrolyte, coagulation function, tumor markers and cytokines were collected before neoadjuvant chemotherapy combined with immunotherapy, after 2 cycles of treatment and after 4 cycles of treatment (if applicable). After every two cycles of treatment, the remission status of the disease was evaluated by CT or gastroscopy in the routine treatment. To evaluate the predictive value and mechanism of peripheral blood inflammatory factors on the prognosis of patients, and to explore the influencing factors of inflammation and tumor microenvironment on the efficacy of neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer.

        The patient's age between 18 to 80 years old; Esophageal squamous cell carcinoma with
        definite pathological diagnosis and II-IVA clinical stage Preoperative neoadjuvant
        chemotherapy combined with immunotherapy The score of eastern cooperative oncology group is
        0 ~ 1 Exclusion criteria
        The estimated survival time is less than 6 months; The first diagnosis had distant
        metastasis Suffering from malignant tumor or accompanying malignant disease in the past 5
        years Pregnant or pregnant women. Vulnerable groups (those without informed ability,
        minors, vagrants, students and subordinates of researchers, employees of bidders)